Literature DB >> 31689676

Resolving intestinal fibrosis through regenerative medicine.

Renate Schwab1, Rebecca Lim2, Rimma Goldberg3.   

Abstract

Crohn's Disease and Ulcerative Colitis, known collectively as Inflammatory Bowel Disease (IBD), are lifelong gastrointestinal disorders that commonly present at a young age and are increasing in incidence and prevalence. Fibrosis is a common and incurable complication of IBD. When fibrotic complications occur, patients often have to undergo disfiguring surgery. Thus, research has focused on regenerative therapies as a means to prevent and treat established fibrosis. Both cell and non-cell therapies (exosomes) have anti-fibrotic and anti-inflammatory properties. This review discusses these emerging therapeutics and their potential to treat intestinal fibrosis.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31689676     DOI: 10.1016/j.coph.2019.09.011

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  4 in total

1.  Resolvin D1 Prevents Epithelial-to-Mesenchymal Transition and Reduces Collagen Deposition by Stimulating Autophagy in Intestinal Fibrosis.

Authors:  Cui Zeng; Xinghuang Liu; Danping Xiong; Kaifang Zou; Tao Bai
Journal:  Dig Dis Sci       Date:  2022-01-10       Impact factor: 3.487

2.  MicroRNA-21-3p Engineered Umbilical Cord Stem Cell-Derived Exosomes Inhibit Tendon Adhesion.

Authors:  Zhixiao Yao; Juehong Li; Xu Wang; Shiqiao Peng; Jiexin Ning; Yun Qian; Cunyi Fan
Journal:  J Inflamm Res       Date:  2020-07-07

Review 3.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

Review 4.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.